Compare ADMA Biologics Inc (ADMA) vs Expeditors International of Wshngtn Inc (EXPD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Expeditors International of Wshngtn Inc — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Expeditors International of Wshngtn Inc trades at $164.43 (market cap $21.68B). The key difference: Expeditors International of Wshngtn Inc is far larger — about 10.2× ADMA Biologics Inc's market cap, and Expeditors International of Wshngtn Inc pays a 0.98% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | EXPD | |
|---|---|---|
Market Cap | $2.13B | $21.68B |
Sector | Health | Industrials |
52-Week High | $20.38 | $167.57 |
52-Week Low | $7.60 | $111.37 |
Enterprise Value | $2.20B | $20.93B |
Dividend Yield | — | 0.98% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
EXPD trades at $165.74, down 1.09% today, with a bullish technical outlook supported by moving averages and strong momentum indicators. The company shows consistent earnings beats, with Q1 2026 EPS of $1.71 surpassing expectations of $1.33. Revenue growth is steady, reaching $11.07B in 2025, while maintaining robust profitability with a net margin of 7.48% and ROE of 36.59%. Recent news highlights EXPD's resilience in transportation services amid industry challenges.
The stock presents a mixed outlook: strong fundamentals and technical momentum support upside potential, but valuation multiples like P/E of 26.77 suggest premium pricing. Risks include economic sensitivity and competitive pressures. Analyst consensus is cautious with 60.61% hold ratings, though price targets indicate limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Expeditors International of Wshngtn Inc
Expeditors International of Washington is a non-asset-based third-party logistics provider, mainly focused on international freight forwarding. It employs sophisticated IT systems and contracts with airlines and ocean carriers to move customers' freight across the globe. The firm operates more than 200 full-service office locations worldwide, in addition to numerous satellite locations. In 2021, Expeditors derived 38% of consolidated net revenue from airfreight, 27% from ocean freight, and 35% from customs brokerage and other services.
Read more on EXPD →
